Allarity falls on going-concern warning
** Allarity Therapeutics' shares ALLR.O fall 4% to $1.46
in extended trade
** Says cash reserves insufficient to fund current operating
plan and planned capital expenditures for next 12 months,
raising "substantial doubt" over co's ability to continue as a
going concern urn:newsml:reuters.com:*:nNDL26Bhft
** Due to significant losses, co has accumulated deficit of
$74.2 mln, as of June 30
** Up to Monday's close, stock had slumped 85% this year
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))
Recent news on Allarity Therapeutics
See all newsBrief: Allarity Therapeutics Announces Strategic Capital Allocation For Filing Of Spac Registration Statement
Allarity Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Allarity Therapeutics Q2 loss narrows as expenses fall
Allarity Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Allarity Therapeutics Announces The Grant Of Essential U.S. Patent For Its Stenoparib Drp® Companion Diagnostic